Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.

Investigational vidofludimus calcium missed its primary target in an exploratory phase II study of progressive multiple sclerosis (MS) but showed promising disability-related trends, data from the ...

Variations in p21 protein activity may help explain why different people with MS develop different types of the disease, a study reports.

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...

NEW YORK, NY, UNITED STATES, March 24, 2026 /EINPresswire.com/ — Scientists at the Tisch Multiple Sclerosis Research Center ...

Multiple sclerosis (MS) is an inflammatory condition that damages the myelin of the central nervous system, leading to neurologic impairment and possibly severe disability. MS is characterized by ...

Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis (MS), show the findings of the INFORMS study. The findings, which are ...

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing ‌its multiple sclerosis drug candidate fenebrutinib against the relapsing form ‌of the disease achieved its ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...